Aura Biosciences Files 8-K Report

Ticker: AURA · Form: 8-K · Filed: 2024-06-04T00:00:00.000Z

Sentiment: neutral

Topics: sec-filing, 8-k, financial-disclosure

TL;DR

Aura Biosciences filed an 8-K, likely with financial updates. Stay tuned.

AI Summary

On June 4, 2024, Aura Biosciences, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and significant occurrences. No specific financial figures or new events were detailed in the provided text.

Why It Matters

This filing signals that Aura Biosciences is providing updated information to the SEC, which could include material events or financial disclosures relevant to investors.

Risk Assessment

Risk Level: low — The filing is a standard SEC disclosure form (8-K) without immediate negative or positive news, making the immediate risk level low.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Aura Biosciences, Inc.?

The filing is primarily for "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and significant occurrences.

When was this 8-K report filed?

The report was filed on June 4, 2024.

What is Aura Biosciences, Inc.'s principal executive office address?

The principal executive office is located at 80 Guest Street, Boston, MA 02135.

What is the SEC file number for Aura Biosciences, Inc.?

The SEC file number is 001-40971.

What is the I.R.S. Employer Identification Number for Aura Biosciences, Inc.?

The I.R.S. Employer Identification Number is 32-0271970.

Filing Stats: 1,067 words · 4 min read · ~4 pages · Grade level 14.9 · Accepted 2024-06-04 17:07:07

Key Financial Figures

Filing Documents

Forward Looking Statements

Forward Looking Statements Statements contained under this Item 8.01 regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements about the initiation, timing, progress, results and cost of our research and development programs and our current and future preclinical studies and clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs; our ability to successfully manufacture our drug substances and product candidates for preclinical use, for clinical trials and on a larger scale for commercial use, if approved; the ability and willingness of our third-party strategic collaborators to continue research and development activities relating to our development candidates and product candidates; our ability to commercialize our products, if approved; our ability to obtain funding for our operations necessary to complete further development and commercialization of our product candidates; our ability to obtain and maintain regulatory approval of our product candidates; the size and growth potential of the markets for our product candidates and our ability to serve those markets; our financial performance; our expected cash runway into the second half of 2026; and the implementation of our business model, including strategic plans for our business and product candidates. Any forward-looking statements are neither promises nor guarantees, and investors should not place undue reliance on these forward-looking statements because they involve known and unknown ris

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Corporate presentation of the Company 104 Cover Page Interactive Data (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 4, 2024 AURA BIOSCIENCES, INC. By: /s/ Julie Feder Julie Feder Chief Financial Officer

View on Read The Filing